Breast cancer in women after withdrawing from an increased-risk MRI screening program.

Suzanne L van Winkel¹, Riccardo Samperna², Elizabeth A Loehrer^2,3, Caroline A Drukker⁴, Kelly Sessink², Nico Karssemeijer^2,5, Ritse M Mann^2,6

¹Medical Imaging Department, Radboudumc: Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. suzanne.vanwinkel@radboudumc.nl.

²Medical Imaging Department, Radboudumc: Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

³Department of Clinical Genetics, Erasmus MC: Erasmus University Medical Center, Rotterdam, The Netherlands.

⁴Department of Surgical Oncology, Netherlands Cancer Institute; Antoni van Leeuwenhoek (NKI), Amsterdam, The Netherlands.

⁵ScreenPoint Medical BV, Nijmegen, The Netherlands.

⁶Department of Radiology, Netherlands Cancer Institute; Antoni van Leeuwenhoek (NKI), Amsterdam, The Netherlands.

PubMed PMC DOI PDF

Abstract

OBJECTIVE: This study evaluates breast cancer (BC) detection in women with ≥ 20% lifetime risk who discontinued annual breast MRI screening surveillance. MATERIALS AND METHODS: This retrospective single screening cohort (2003-2019) study included 3308 women who received at least one breast MRI. After verifying with the Netherlands Comprehensive Cancer Organization (IKNL), a sub-population of wome…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.